[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,973,963
  • Shares Outstanding, K 144,648
  • Annual Sales, $ 62,380 K
  • Annual Income, $ -101,590 K
  • EBIT $ -110 M
  • EBITDA $ -111 M
  • 60-Month Beta 1.22
  • Price/Sales 57.67
  • Price/Cash Flow N/A
  • Price/Book 9.16

Options Overview Details

View History
  • Implied Volatility 123.33% (-6.89%)
  • Historical Volatility 95.86%
  • IV Percentile 8%
  • IV Rank 17.92%
  • IV High 538.02% on 12/17/25
  • IV Low 32.80% on 09/04/25
  • Expected Move (DTE 31) 5.27 (25.68%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 320
  • Volume Avg (30-Day) 1,140
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 6,461
  • Open Int (30-Day) 12,909
  • Expected Range 15.25 to 25.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.33
  • Number of Estimates 6
  • High Estimate $-0.29
  • Low Estimate $-0.40
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) +5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.34 +5.86%
on 05/15/26
28.41 -27.93%
on 04/21/26
-6.16 (-23.14%)
since 04/17/26
3-Month
10.80 +89.58%
on 03/02/26
28.41 -27.93%
on 04/21/26
+8.07 (+64.99%)
since 02/18/26
52-Week
1.47 +1,292.86%
on 05/19/25
28.41 -27.93%
on 04/21/26
+18.98 (+1,265.00%)
since 05/16/25

Most Recent Stories

More News
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection...

TNGX : 20.66 (+0.49%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 20.66 (+0.49%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 20.66 (+0.49%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 20.66 (+0.49%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted...

TNGX : 20.66 (+0.49%)
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

-  Matthew Gall appointed Chief Financial Officer  - -  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026...

TNGX : 20.66 (+0.49%)
This Stock Is Up 1,229% in Just the Past Year, But Don’t Bet Your Retirement Money on It

Tango Therapeutics (TNGX) has surged 1,229% over the past year. Shares are trading at a new all-time high and have strong technical momentum. TNGX maintains a 100% “Buy” technical opinion from Barchart....

TNGX : 20.66 (+0.49%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors...

TNGX : 20.66 (+0.49%)
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical...

TNGX : 20.66 (+0.49%)
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S....

TNGX : 20.66 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 26.75
2nd Resistance Point 25.03
1st Resistance Point 22.79
Last Price 20.66
1st Support Level 18.83
2nd Support Level 17.11
3rd Support Level 14.88

See More

52-Week High 28.41
Last Price 20.66
Fibonacci 61.8% 18.12
Fibonacci 50% 14.94
Fibonacci 38.2% 11.76
52-Week Low 1.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.